Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of degarelix versus GnRH agonist in advanced prostate cancer with cardiovascular risk
MOH_2020-01-07_008597Phase 2Not yet recruiting
- Sponsor
- פרופ' דוד מרגל
- Start
- Dec 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of degarelix in prostate cancer (PCa) (2 arms), sponsored by פרופ' דוד מרגל. Primary endpoint: Cardiovascular event rate. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2020-01-07_008597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-01-07_008597.